STAT+: State laws may be curbing private equity takeovers of physician group
Private equity deals for practice management firms are declining sharply.
STAT
Reporting from the frontiers of health and medicine
Latest posts
STAT+: Epic’s alleged anticompetitive practices under scrutiny from federal, state investigators
Epic Systems is the subject of a broad inquiry into its business practices, people who were contacted by FTC investigators told STAT.
Opinion: AAP president: How pediatricians are navigating federal leaders’ fearmongering on vaccines
Every parent experiences a unique mix of emotions when caring for a newborn baby. You’re filled with an overwhelming sense of pride, love, and awe for this tiny, precious person…
Luigi Mangione pleads guilty to federal stalking charges in the killing of UnitedHealthcare CEO
In pleading guilty, Mangione admitted to following UnitedHealth executive Brian Thompson and then shooting him.
STAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
STAT+: PBMs agree to display TrumpRx drug prices
Bristol's Zenbexus wins accelerated approval, Novartis wins UK patent fight over Entresto, and more biotech news from The Readout
STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
The FDA approved a Bristol oral treatment for advanced multiple myeloma, marking the debut of a new class of medicine for the blood cancer
STAT+: Drug-testing lab that has sparked controversy sues group that develops drug standards over criticism
A lab that tussled with regulators over impurities found in widely used medicines has accused U.S. Pharmacopeia of making false and misleading remarks about its methods.
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.
How will legal challenges fare against CMS rule on gender-affirming care?
A CMS rule finalized this week may prove more difficult to challenge than previous Trump administration actions to end transgender care for young people.
Opinion: MAHA and insurance companies both want to treat human bodies like cars
“If the short history of telematics in the auto insurance taught us anything, it’s to be skeptical of any promises attached to shareable surveillance data.”
Two years after rules overhaul, have methadone clinics really changed?
Methadone clinics don't have to be as rigid in how they dispense opioid addiction medicine. Some, though not all, are changing their ways.
Opinion: U.S., U.K. health care systems share a fatal flaw
“The default to biomedical responses means that clinics and hospitals are increasingly absorbing the costs of social problems,” writes Kyle Vanelli.
STAT+: Commure terminates payments under its customer referral programs tied to AI products
Commure, which develops and sells AI products to clinics, has terminated a program that paid for referrals to new customers.
STAT+: Eli Lilly targets booming black market for retatrutide
Khartis raises oral immunology funds, Neurocrine drug safety concerns, and more biotech news from The Readout
STAT+: Kennedy heads west, slams Becerra
The health secretary headed to California to lay out the government's new approach to addiction treatment.
STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and more
Seven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 each
STAT+: An investigation into Commure, and Medicare’s new-tech incentives for AI devices
In this edition of STAT Health Tech: a deep dive into General Catalyst-backed Commure, and Medicare's tech incentives for AI devices.
STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk
When it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus. Such is the case with a therapy from Neurocrine Biosciences.
STAT+: What patients actually think about ‘minimally invasive’ brain implants
A new study polled people with treatment-resistant depression about what matters to them when it comes to brain implants for mental health.